Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 291

1.

Baseline glucocorticoid dose and bone mineral density response with teriparatide or alendronate therapy in patients with glucocorticoid-induced osteoporosis.

Devogelaer JP, Adler RA, Recknor C, See K, Warner MR, Wong M, Krohn K.

J Rheumatol. 2010 Jan;37(1):141-8. doi: 10.3899/jrheum.090411. Epub 2009 Nov 16.

PMID:
19918047
[PubMed - indexed for MEDLINE]
2.

Correlations between biochemical markers of bone turnover and bone density responses in patients with glucocorticoid-induced osteoporosis treated with teriparatide or alendronate.

Burshell AL, Möricke R, Correa-Rotter R, Chen P, Warner MR, Dalsky GP, Taylor KA, Krege JH.

Bone. 2010 Apr;46(4):935-9. doi: 10.1016/j.bone.2009.12.032. Epub 2010 Jan 6.

PMID:
20060081
[PubMed - indexed for MEDLINE]
3.

Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial.

Saag KG, Zanchetta JR, Devogelaer JP, Adler RA, Eastell R, See K, Krege JH, Krohn K, Warner MR.

Arthritis Rheum. 2009 Nov;60(11):3346-55. doi: 10.1002/art.24879.

PMID:
19877063
[PubMed - indexed for MEDLINE]
Free Article
4.

Teriparatide or alendronate in glucocorticoid-induced osteoporosis.

Saag KG, Shane E, Boonen S, Marín F, Donley DW, Taylor KA, Dalsky GP, Marcus R.

N Engl J Med. 2007 Nov 15;357(20):2028-39.

PMID:
18003959
[PubMed - indexed for MEDLINE]
Free Article
5.

Active comparator trial of teriparatide vs alendronate for treating glucocorticoid-induced osteoporosis: results from the Hispanic and non-Hispanic cohorts.

Losada BR, Zanchetta JR, Zerbini C, Molina JF, De la Peña P, Liu CC, Smith RB, Nino AJ, Krohn K, Warner MR.

J Clin Densitom. 2009 Jan-Mar;12(1):63-70. doi: 10.1016/j.jocd.2008.10.002. Epub 2008 Nov 22.

PMID:
19028124
[PubMed - indexed for MEDLINE]
6.

Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis.

Gallagher JC, Rosen CJ, Chen P, Misurski DA, Marcus R.

Bone. 2006 Dec;39(6):1268-75. Epub 2006 Aug 1.

PMID:
16884968
[PubMed - indexed for MEDLINE]
7.

Alendronate and indapamide alone or in combination in the management of hypercalciuria associated with osteoporosis: a randomized controlled trial of two drugs and three treatments.

Giusti A, Barone A, Pioli G, Girasole G, Siccardi V, Palummeri E, Bianchi G.

Nephrol Dial Transplant. 2009 May;24(5):1472-7. doi: 10.1093/ndt/gfn690. Epub 2008 Dec 15.

PMID:
19075192
[PubMed - indexed for MEDLINE]
Free Article
8.

Positive effect of alendronate on bone mineral density and markers of bone turnover in patients with rheumatoid arthritis on chronic treatment with low-dose prednisone: a randomized, double-blind, placebo-controlled trial.

Lems WF, Lodder MC, Lips P, Bijlsma JW, Geusens P, Schrameijer N, van de Ven CM, Dijkmans BA.

Osteoporos Int. 2006;17(5):716-23. Epub 2006 Feb 3.

PMID:
16463007
[PubMed - indexed for MEDLINE]
9.

Bisphosphonates and glucocorticoid osteoporosis in men: results of a randomized controlled trial comparing zoledronic acid with risedronate.

Sambrook PN, Roux C, Devogelaer JP, Saag K, Lau CS, Reginster JY, Bucci-Rechtweg C, Su G, Reid DM.

Bone. 2012 Jan;50(1):289-95. doi: 10.1016/j.bone.2011.10.024. Epub 2011 Oct 29. Erratum in: Bone. 2012 Mar;50(3):811.

PMID:
22061864
[PubMed - indexed for MEDLINE]
10.

Once-weekly oral alendronate 70 mg in patients with glucocorticoid-induced bone loss: a 12-month randomized, placebo-controlled clinical trial.

Stoch SA, Saag KG, Greenwald M, Sebba AI, Cohen S, Verbruggen N, Giezek H, West J, Schnitzer TJ.

J Rheumatol. 2009 Aug;36(8):1705-14. doi: 10.3899/jrheum.081207. Epub 2009 Jun 1.

PMID:
19487264
[PubMed - indexed for MEDLINE]
11.

Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate.

Ettinger B, San Martin J, Crans G, Pavo I.

J Bone Miner Res. 2004 May;19(5):745-51. Epub 2004 Jan 19.

PMID:
15068497
[PubMed - indexed for MEDLINE]
12.

Post hoc analysis of a single IV infusion of zoledronic acid versus daily oral risedronate on lumbar spine bone mineral density in different subgroups with glucocorticoid-induced osteoporosis.

Roux C, Reid DM, Devogelaer JP, Saag K, Lau CS, Reginster JY, Papanastasiou P, Bucci-Rechtweg C, Su G, Sambrook PN.

Osteoporos Int. 2012 Mar;23(3):1083-90. doi: 10.1007/s00198-011-1800-1.

PMID:
21975559
[PubMed - indexed for MEDLINE]
13.

Teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: an analysis by gender and menopausal status.

Langdahl BL, Marin F, Shane E, Dobnig H, Zanchetta JR, Maricic M, Krohn K, See K, Warner MR.

Osteoporos Int. 2009 Dec;20(12):2095-104. doi: 10.1007/s00198-009-0917-y. Epub 2009 Apr 7.

PMID:
19350340
[PubMed - indexed for MEDLINE]
14.

Effects of teriparatide and alendronate on vertebral strength as assessed by finite element modeling of QCT scans in women with osteoporosis.

Keaveny TM, Donley DW, Hoffmann PF, Mitlak BH, Glass EV, San Martin JA.

J Bone Miner Res. 2007 Jan;22(1):149-57.

PMID:
17042738
[PubMed - indexed for MEDLINE]
15.

Effect of teriparatide on bone mineral density and biochemical markers in Japanese women with postmenopausal osteoporosis: a 6-month dose-response study.

Miyauchi A, Matsumoto T, Shigeta H, Tsujimoto M, Thiebaud D, Nakamura T.

J Bone Miner Metab. 2008;26(6):624-34. doi: 10.1007/s00774-008-0871-3. Epub 2008 Nov 1.

PMID:
18979163
[PubMed - indexed for MEDLINE]
16.

Changes in bone mineral density following discontinuation or continuation of alendronate therapy in glucocorticoid-treated patients: a retrospective, observational study.

Emkey R, Delmas PD, Goemaere S, Liberman UA, Poubelle PE, Daifotis AG, Verbruggen N, Lombardi A, Czachur M.

Arthritis Rheum. 2003 Apr;48(4):1102-8.

PMID:
12687554
[PubMed - indexed for MEDLINE]
Free Article
17.

Femoral strength in osteoporotic women treated with teriparatide or alendronate.

Keaveny TM, McClung MR, Wan X, Kopperdahl DL, Mitlak BH, Krohn K.

Bone. 2012 Jan;50(1):165-70. doi: 10.1016/j.bone.2011.10.002. Epub 2011 Oct 17.

PMID:
22015818
[PubMed - indexed for MEDLINE]
18.

Bone formation markers in patients with glucocorticoid-induced osteoporosis treated with teriparatide or alendronate.

Eastell R, Chen P, Saag KG, Burshell AL, Wong M, Warner MR, Krege JH.

Bone. 2010 Apr;46(4):929-34. doi: 10.1016/j.bone.2009.12.021. Epub 2010 Jan 6.

PMID:
20060078
[PubMed - indexed for MEDLINE]
19.

Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis.

Chen P, Satterwhite JH, Licata AA, Lewiecki EM, Sipos AA, Misurski DM, Wagman RB.

J Bone Miner Res. 2005 Jun;20(6):962-70. Epub 2005 Jan 18.

PMID:
15883636
[PubMed - indexed for MEDLINE]
20.

Effect of raloxifene after recombinant teriparatide [hPTH(1-34)] treatment in postmenopausal women with osteoporosis.

Adami S, San Martin J, Muñoz-Torres M, Econs MJ, Xie L, Dalsky GP, McClung M, Felsenberg D, Brown JP, Brandi ML, Sipos A.

Osteoporos Int. 2008 Jan;19(1):87-94. Epub 2007 Oct 16.

PMID:
17938984
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk